(UroToday.com) In a point and counterpoint format at the 2020 Society of Urologic Oncology (SUO) virtual meeting discussing whether PSMA PET-CT is ready for prime-time use, Dr. Tanya Dorff took the “pro” point approach that prostate-specific membrane antigen (PSMA) PET-CT is ready for prime-time use and may fill an unmet need in the treatment of prostate cancer. These unmet needs include high-risk localized disease, biochemical recurrence, oligometastatic, and mCRPC as summarized in the following figure: